Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Arterial Hypertension
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 21, No 1 (2017)
Editorial
Published online: 2017-03-30
View PDF (Polish) Download PDF file
Get Citation

Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym

Krystyna Widecka, Filip M. Szymański, Krzysztof J. Filipiak, Jacek Imiela, Beata Wożakowska-Kapłon, Eugeniusz J. Kucharz, Artur Mamcarz, Jacek Manitius, Andrzej Tykarski
DOI: 10.5603/AH.2017.0001
·
Arterial Hypertension 2017;21(1):1-9.

open access

Vol 21, No 1 (2017)
Editorial
Published online: 2017-03-30

Abstract

Not available

Abstract

Not available

Full Text:

View PDF (Polish) Download PDF file
Get Citation
About this article
Title

Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym

Journal

Arterial Hypertension

Issue

Vol 21, No 1 (2017)

Article type

Editorial

Pages

1-9

Published online

2017-03-30

Page views

2389

Article views/downloads

14646

DOI

10.5603/AH.2017.0001

Bibliographic record

Arterial Hypertension 2017;21(1):1-9.

Authors

Krystyna Widecka
Filip M. Szymański
Krzysztof J. Filipiak
Jacek Imiela
Beata Wożakowska-Kapłon
Eugeniusz J. Kucharz
Artur Mamcarz
Jacek Manitius
Andrzej Tykarski

References (52)
  1. Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016; 213: 8–14.
    CrossRefPubMed
  2. Dalbeth N, Merriman T, Stamp L. Gout. The Lancet. 2016; 388(10055): 2039–2052.
    CrossRef
  3. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000; 27(6): 1501–1505.
    PubMed
  4. Norvik JV, Storhaug HM, Ytrehus K, et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study. BMC Cardiovasc Disord. 2016; 16: 85–98.
    CrossRefPubMed
  5. Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases. 2014; 73(8): 1470–1476.
    CrossRefPubMed
  6. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014; 40(2): 155–175.
    CrossRefPubMed
  7. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004; 4: 9.
    CrossRefPubMed
  8. Qiu L, Cheng Xq, Wu J, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health. 2013; 13: 664.
    CrossRefPubMed
  9. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006; 48(6): 1031–1036.
    CrossRefPubMed
  10. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007; 25(8): 1583–1589.
    CrossRefPubMed
  11. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993; 14(6): 615–631.
    PubMed
  12. Ruggiero C, Cherubini A, Lauretani F, et al. Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord. 2009; 27(4): 382–389.
    CrossRefPubMed
  13. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17): 1811–1821.
    CrossRefPubMed
  14. Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid and oxidative stress. Curr Pharm Des. 2005; 11(32): 4145–4151.
    PubMed
  15. Abeles AM. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015; 17(3): 13.
    CrossRefPubMed
  16. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 608–619.
    CrossRefPubMed
  17. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008; 58(2): 623–630.
    CrossRefPubMed
  18. Puddu P, Puddu GM, Cravero E, et al. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol. 2012; 59(3): 235–242.
    CrossRefPubMed
  19. Lee JE, Kim YG, Choi YH, et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006; 47(5): 962–967.
    CrossRefPubMed
  20. Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985; 121(1): 11–18.
    PubMed
  21. Ndrepepa G, Braun S, Haase HU, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012; 109(9): 1260–1265.
    CrossRefPubMed
  22. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1998; 95(2): 675–680.
    PubMed
  23. Spitsin SV, Scott GS, Mikheeva T, et al. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med. 2002; 33(10): 1363–1371.
    PubMed
  24. Chamorro A, Obach V, Cervera A, et al. Prognostic Significance of Uric Acid Serum Concentration in Patients With Acute Ischemic Stroke. Stroke. 2002; 33(4): 1048–1052.
    CrossRef
  25. Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005; 9(3): 195–205.
    CrossRefPubMed
  26. Perez-Ruiz F, Becker MA. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2: 9–14.
    CrossRefPubMed
  27. Kucharz EJ. Chronic inflammation-enhanced atherosclerosis: can we consider it as a new clinical syndrome? Med Hypotheses. 2012; 78(3): 396–397.
    CrossRefPubMed
  28. Amaro S, Soy D, Obach V, et al. A Pilot Study of Dual Treatment With Recombinant Tissue Plasminogen Activator and Uric Acid in Acute Ischemic Stroke. Stroke. 2007; 38(7): 2173–2175.
    CrossRef
  29. Duan W, Ladenheim B, Cutler RG, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002; 80(1): 101–110.
    PubMed
  30. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 608–619.
    CrossRefPubMed
  31. Imaram W, Gersch C, Kim KM, et al. Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med. 2010; 49(2): 275–281.
    CrossRefPubMed
  32. Akkineni R, Tapp S, Tosteson ANA, et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J Rheumatol. 2014; 41(4): 739–748.
    CrossRefPubMed
  33. Widecka K, Grodzicki T, Narkiewicz K, et al. Zasady postępowania w nadciśnieniu tętniczym - 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze. 2011; 15: 55–82.
  34. Mancia G, Fagard R, Narkiewicz K, et al. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Nadciśnienie Tętnicze. 2013; 17(2): 69–168.
  35. Tykarski A, Narkiewicz K, Gaciong Z, et al. 2015 Guidelines for the Management of Hypertension. Part 1–7. Recommendations of the Polish Society of Hypertension. Arterial Hypertens. 2015; 19(2): 53–83.
    CrossRef
  36. Høieggen A, Alderman MH, Kjeldsen SE, et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65(3): 1041–1049.
    CrossRefPubMed
  37. Armstrong C. Joint National Committee. JNC 8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014; 90(7): 503–4.
    PubMed
  38. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011; 19(6): 265–271.
    CrossRefPubMed
  39. Milurit - charakterystyka produktu leczniczego. www.mz.gov.pl/leki/produkty lecznicze/charakterystyka-produktów leczniczych.
  40. Seth R, Kydd A, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database of Systematic Reviews. 2014.
    CrossRefPubMed
  41. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23): 2450–2461.
    CrossRefPubMed
  42. Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009; 48(7): 804–806.
    CrossRefPubMed
  43. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015; 74(7): 1368–1372.
    CrossRefPubMed
  44. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013; 15(6): 435–442.
    CrossRefPubMed
  45. Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Ann Med. 2017; 49(2): 142–156.
    CrossRefPubMed
  46. Deng G, Qiu Z, Li D, et al. Effects of Allopurinol on Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials. Med Sci Monit. 2016; 22: 1389–1397.
    PubMed
  47. Ekici B, Kütük U, Alhan A, et al. The relationship between serum uric acid levels and angiographic severity of coronary heart disease. Kardiol Pol. 2015; 73(7): 533–538.
    CrossRefPubMed
  48. Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996; 312(7024): 173–174.
    PubMed
  49. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349(17): 1647–1655.
    CrossRefPubMed
  50. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64(8): 2529–2536.
    CrossRefPubMed
  51. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006; 40(12): 2187–2194.
    CrossRefPubMed
  52. Adenuric - charakterystyka produktu leczniczego. www.mz.gov.pl/leki/produkty lecznicze/charakterystyka-produktów leczniczych.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl